Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jun 17;28(28):4478-86. doi: 10.1016/j.vaccine.2010.04.039. Epub 2010 Apr 29.

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Author information

1
Department of Pathology, Johns Hopkins University, Baltimore, MD 21231, USA.

Abstract

Immunization with L1 as pentavalent capsomeres or virus-like particles (VLPs) generates high and long-lived titers of neutralizing antibodies and protection primarily against the human papillomavirus (HPV) type from which the vaccine was derived. Conversely, vaccination with L2 minor capsid protein derived from multiple HPV types induces lower titer, but more broadly neutralizing and protective antibody responses. We combined the advantages of each protective antigen by immunization with titrated doses of multi-type L2 with either L1 capsomeres or VLP. We observed no significant interference between the L1 and L2 antibody response upon co-administration of L1 vaccines with multi-type L2 vaccines.

PMID:
20434552
PMCID:
PMC2918737
DOI:
10.1016/j.vaccine.2010.04.039
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center